On November 3, 2022 Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, reported that four abstracts highlighting ziftomenib, the Company’s potent and selective menin inhibitor, have been accepted for presentation at the upcoming American Society of Hematology (ASH) (Free ASH Whitepaper) Annual Meeting, to be held in New Orleans from December 10-13, 2022 (Press release, Kura Oncology, NOV 3, 2022, View Source [SID1234622899]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"We are honored that several abstracts showcasing our menin inhibitor program have been selected for presentation, including an oral presentation of updated data from our KOMET-001 trial of ziftomenib in relapsed/refractory acute myeloid leukemia," said Stephen Dale, M.D., Chief Medical Officer of Kura Oncology. "We look forward to sharing more details on the program, building upon its potential to make a substantial impact in improving patient outcomes in an important area of unmet need."
Session titles and information for the four abstracts are listed below and are now available on the ASH (Free ASH Whitepaper) online itinerary planner.
Update on a Phase 1/2 First-in-Human Study of the Menin-KMT2A (MLL) Inhibitor Ziftomenib (KO-539) in Patients with Relapsed or Refractory Acute Myeloid Leukemia
Session Name: 616. Acute Myeloid Leukemias: Investigational Therapies, Excluding Transplantation and Cellular Immunotherapies: Relapsed/Refractory AML
Session Date and Time: Saturday, December 10, 2022; 9:30 AM – 11:00 AM CT
Oral Presentation Time: 10:15 AM CT
Location: New Orleans, Ernest N. Morial Convention Center, Rooms 220-222
Publication Number: 64
Preclinical In Vivo Activity of the Menin Inhibitor Ziftomenib (KO-539) in Pediatric KMT2A-Rearranged Acute Lymphoblastic Leukemia
Session Name: 618. Acute Lymphoblastic Leukemias: Biomarkers, Molecular Markers and Minimal Residual Disease in Diagnosis and Prognosis: Poster I
Session Date and Time: Saturday, December 10, 2022; 5:30 PM – 7:30 PM CT
Location: New Orleans, Ernest N. Morial Convention Center, Hall D
Publication Number: 1516
The Menin Inhibitor Ziftomenib (KO-539) Synergizes with Agents Targeting Chromatin Regulation or Apoptosis and Sensitizes AML with MLL Rearrangement or NPM1 Mutation to Venetoclax
Session Name: 616. Acute Myeloid Leukemias: Investigational Therapies, Excluding Transplantation and Cellular Immunotherapies: Poster II
Session Date and Time: Sunday, December 11, 2022; 6:00 PM – 8:00 PM CT
Location: New Orleans, Ernest N. Morial Convention Center, Hall D
Publication Number: 2770
Novel Combination of Clinical Menin Inhibitor Ziftomenib and the Nuclear Export Inhibitor Selinexor Synergistically Inhibit MLL-r AML
Session Name: 604. Molecular Pharmacology and Drug Resistance: Myeloid Neoplasms: Poster III
Session Date and Time: Monday, December 12, 2022; 6:00 PM – 8:00 PM
Location: New Orleans, Ernest N. Morial Convention Center, Hall D
Publication Number: 3969